Microdosing
E829288
Microdosing is the practice of regularly taking very small, sub-perceptual doses of psychedelic substances, often with the aim of enhancing mood, creativity, or cognitive performance without inducing a full psychedelic experience.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
Drug administration regimen
ⓘ
Psychedelic drug use practice ⓘ |
| aimsToAvoid |
Full psychedelic experience
ⓘ
Overt hallucinations ⓘ |
| becamePopularIn | 2010s ⓘ |
| differsFrom |
Conventional psychiatric pharmacotherapy
ⓘ
Macrodosing of psychedelics ⓘ |
| hasAdministrationPattern |
Regular schedule
ⓘ
Repeated dosing over weeks or months ⓘ |
| hasCommonSchedule |
Dosing every few days
GENERATED
ⓘ
Dosing followed by rest days GENERATED ⓘ |
| hasDefinition | Practice of taking very small, sub-perceptual doses of psychoactive substances ⓘ |
| hasDoseCharacteristic |
Fraction of a typical recreational dose
ⓘ
Sub-perceptual ⓘ |
| hasEvidenceStatus |
Limited clinical evidence
ⓘ
Primarily supported by anecdotal reports ⓘ |
| hasGoal |
Enhance cognitive performance
ⓘ
Enhance creativity ⓘ Enhance mood ⓘ Improve focus ⓘ Increase productivity ⓘ Support mental health ⓘ |
| hasMeasurementUnit |
Micrograms for LSD
ⓘ
Milligrams for psilocybin or dried mushrooms ⓘ |
| hasRegulatoryStatus | Often involves controlled substances ⓘ |
| hasReportedEffect |
Enhanced problem-solving
GENERATED
ⓘ
Improved concentration GENERATED ⓘ Increased emotional openness GENERATED ⓘ Increased energy GENERATED ⓘ Reduced anxiety GENERATED ⓘ Reduced depressive symptoms GENERATED ⓘ Subtle changes in perception GENERATED ⓘ |
| hasRisk |
Difficulty in accurate dose measurement
ⓘ
Legal consequences in many jurisdictions ⓘ Possible cardiovascular effects depending on substance ⓘ Potential psychological adverse effects ⓘ Unknown long-term health effects ⓘ |
| hasTypicalSubstance |
Lysergic acid diethylamide
ⓘ
Mescaline NERFINISHED ⓘ Other psychedelic compounds ⓘ Psilocybin NERFINISHED ⓘ Psilocybin-containing mushrooms ⓘ |
| isAssociatedWith |
Biohacking communities
ⓘ
Creative professionals ⓘ Technology industry workers ⓘ |
| isSubjectOf |
Debate about efficacy and safety
ⓘ
Ongoing scientific research ⓘ |
| requires |
Awareness of legal status of substances
ⓘ
Careful dose titration ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.